Overview

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinoma

Phase:

Phase 2

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Antibodies, Monoclonal
Docetaxel
Durvalumab
Oxaliplatin
Tremelimumab